Acor­da cel­e­brates an FDA OK — so does that make them a takeover tar­get?

Late Fri­day, with the gov­ern­ment shut­down loom­ing, the biotech re­port­ed that the FDA has ap­proved their in­haled lev­odopa ther­a­py In­bri­ja for Parkin­son’s pa­tients, putting the com­pa­ny on a short path to a cru­cial­ly need­ed mar­ket launch.

Acor­da $ACOR had been look­ing at a PDU­FA date in ear­ly Jan­u­ary. But with the FDA rack­ing up a record num­ber of ap­provals this year — and its third on Fri­day — the com­pa­ny was giv­en a lit­tle bit of an added edge for its 2019 roll­out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER